Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target upped by Deutsche Bank Aktiengesellschaft from $135.00 to $155.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 2.10% from the stock’s previous close.

Other analysts have also issued reports about the company. UBS Group lifted their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Citigroup lifted their target price on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Scotiabank increased their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday. Finally, Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $152.42.

Gilead Sciences Stock Down 2.6%

GILD opened at $151.81 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The company’s 50-day moving average is $129.59 and its 200 day moving average is $121.98. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market capitalization of $188.35 billion, a P/E ratio of 22.42, a PEG ratio of 0.81 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the firm posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares in the company, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 319,391 shares of company stock worth $44,141,101 in the last 90 days. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of GILD. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $27,000. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. Finally, Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.